FDA Clears Blood Test to Aid Alzheimer's Diagnosis
The Lumipulse test is the first blood test the FDA has authorized to help diagnose the disease.
Updated on Nov. 16, 2026 in Alzheimer’s

The FDA cleared the Lumipulse blood test in May 2025 as an aid in diagnosing Alzheimer's disease in patients 55 and older who already show signs of cognitive decline. The agency says the test cannot diagnose the disease on its own.
Why it matters
Confirming amyloid plaques previously often required brain imaging or spinal fluid testing, which are more invasive and costly. A simpler blood test could make it easier for patients to get an initial assessment of the disease's biological markers.
A positive Lumipulse result indicates a greater than 90% chance that amyloid plaques are present in the brain, a figure the FDA cleared as an aid rather than a standalone diagnosis. The report does not specify the test's performance on negative results or how often it will be used in practice.
The players
U.S. Food and Drug Administration (FDA)
The federal agency responsible for regulating drugs, medical devices and diagnostic tests in the United States, which cleared the Lumipulse test.
The details
The Lumipulse test detects biomarkers associated with amyloid plaques, abnormal protein deposits that build up in the brains of people with Alzheimer's. Doctors must interpret results alongside a patient's medical history, cognitive assessments and other clinical information.
Timeline
2022: Kathi Rigby of Fort Wayne, Ind., is diagnosed with Alzheimer's disease.
May 2025: The FDA clears the Lumipulse blood test.
Roadmap
The clearance builds on a shift toward biomarker-based diagnosis of Alzheimer's, where amyloid detection once required brain imaging or spinal fluid testing. It positions blood-based testing as a less invasive first step within that broader diagnostic pathway.
Patients 55 and older with cognitive symptoms may be able to ask their doctor whether a blood-based test could help assess amyloid plaques. The test is an aid to diagnosis, so results must be reviewed with a clinician alongside other evaluations.
The takeaway
Blood-based biomarker tests may make early assessment of Alzheimer's more accessible, but they work best as one part of a clinical evaluation. Patients experiencing memory or cognitive changes should discuss testing options with their doctor.
Further reading
Explore more on Alzheimer's to see how diagnosis and treatment are evolving.
Source note: This article includes information reported by WOWO 1190 AM | 107.5 FM.










